Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112577 · ClinicalTrials.gov registry record · Phase 1
Study of REGN3500 and Dupilumab in Patients With Asthma
A Phase 1 study of Asthma, Allergic, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 5
- Study locations
NCT03112577: Completed Phase 1 study of Asthma, Allergic, sponsored by Regeneron Pharmaceuticals.
NCT03112577 is a Phase 1 study of Asthma, Allergic that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03112577, a Phase 1 study of Asthma, Allergic, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 5
- Study locations
Study Summary
To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with those at screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG REGN3500
- DRUG Fluticasone propionate
Study Locations (5)
Other
- Celerion - Belfast
- Hammersmith Medicine Research - London
- Respiratory Clinical Trials Ltd - London
- The Medicines Evaluation Unit - Manchester
California
- WCCT Global - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2019-12-09 |
| Phase | Phase 1 |
What the finished NCT03112577 record still lists
NCT03112577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Asthma, Allergic appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03112577 lists 5 locations in 2 states (Other, California).
Frequently Asked Questions
What is clinical trial NCT03112577 about?
NCT03112577 is a clinical study titled "Study of REGN3500 and Dupilumab in Patients With Asthma". To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after treatment initiation compared with...
What is the current status of trial NCT03112577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-06-15. Estimated completion is 2019-12-09.
What conditions does trial NCT03112577 study?
This clinical trial studies the following conditions: Asthma, Allergic.
What interventions are being tested in trial NCT03112577?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), REGN3500 (DRUG), Fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT03112577?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03112577 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma, Allergic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03112577's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI